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Pituitary adenomas are the most common cause of a sellar mass. Metastases to the pituitary gland, a rare occurrence, may mimic
benign pituitary adenomas. We report here a case of a 61-year-old woman with an 80-pack-year smoking history who presented
withheadacheanddiplopia.Visualﬁeldtestingdemonstratedbitemporalhemianopsia.PituitaryMRIrevealeda2.0cmsellarmass
impinging upon the optic chiasm. Hypopituitarism was present, with no evidence of diabetes insipidus. The patient was referred
to our service for transsphenoidal resection of a presumed pituitary macroadenoma. As part of her preoperative evaluation, a
chest radiograph was obtained, which showed a large hilar mass. In light of the patient’s extensive smoking history, the diﬀerential
diagnosis was expanded to include metastatic lesion to the sella. Transsphenoidal resection of the tumor was performed and
histopathology revealed small cell carcinoma. The patient received chemotherapy, but died 18 months later due to widespread
brainmetastases.Althoughthepresenceofdiabetesinsipidusmayhelptodiscriminatebetweenpituitaryadenomasandmetastatic
lesions,thisisnotasensitiveﬁnding.Thiscaseillustratestheneedformaintainingahighindexofsuspicionforpituitarymetastasis
in patients with known risk factors for malignancy.
1.Introduction
The most common cause of an intrasellar lesion is a benign
pituitary adenoma [1]. These tumors can be discovered
incidentallyormaybecomeapparentfromsymptomsrelated
to hormonal hypersecretion, hypopituitarism, diabetes in-
sipidus, or mass eﬀect on adjacent sellar structures. Rarely, a
patient presenting with an apparent pituitary adenoma may,
in fact, be harboring a malignancy that has metastasized to
the sella. Metastatic lesions to the pituitary gland are un-
common and comprise less than 1% of pituitary tumors
overall [2]. Distinguishing between a pituitary adenoma and
a metastatic lesion on clinical grounds can be challenging
given the overlap between symptoms of hypopituitarism and
systemic malignancy. Furthermore, there are no clear-cut
radiographic ﬁndings speciﬁc to metastatic lesions. One
important clue to the diagnosis is the presence of diabetes
insipidus, which is uncommon in pituitary adenomas but
may occur in up to 70% of patients with metastatic disease
[2]. As illustrated by this case, the sensitivity of this ﬁnding
is clearly inferior to its speciﬁcity.
2. Case Presentation
We present the case of a 61-year-old woman with an eighty-
pack-year smoking history who developed fatigue, anorexia,
nausea, and a 11kg weight loss over the course of one2 Case Reports in Medicine
month. She complained of new-onset frontal headaches,
requiring acetaminophen twice daily, and nausea, mitigated
by prochlorperazine. Prior to these symptoms, she was
very active and was employed at a steel mill. She ini-
tially attributed her symptoms to a viral illness, however
within a few days she began to experience diplopia and
diminished visual acuity and sought evaluation from her
regular optometrist. She was noted to have raised intraocular
pressure and was referred to our eye emergency room. An
ophthalmology exam conﬁrmed that she had raised intraoc-
ular pressure and bitemporal hemianopsia by perimetry.
Magnetic resonance imaging demonstrated a 2.0 × 1.2 ×
1.1cm bilobed homogeneous enhancing mass expanding the
sella with compression of the optic chiasm, suggestive of a
pituitary adenoma (Figure 1).
The patient had a history of hypothyroidism subsequent
to radioactive iodine therapy for Graves’ disease. She was
taking levothyroxine, and her previous thyroid function tests
had been normal. She denied galactorrhea, bruising, acne, or
striae. She had noted increasing thirst but denied polyuria.
She felt that her shoes were slightly tighter, but she had no
overt features of acromegaly. Trace pedal edema was noted.
Although the patient had a history of hypertension, she had
recently been experiencing postural hypotension oﬀ of all
of her antihypertensive medications. Clinically, there was no
evidence of a functioning pituitary tumor, though there was
a clear concern about adrenal insuﬃciency.
A hormonal evaluation showed serum prolactin 92.1ng/
mL (normal 3–29), morning cortisol 4.6mcg/dL (4.3–22.4),
LH <0.2mIU/mL, FSH 1.6mIU/mL, estradiol <20pmol/L
(postmenopausal <115), IGF-I 133ng/mL (114–492), TSH
<0.01mIU/mL (0.5–4.7), and free T4 1.36ng/dL (0.8–1.7).
Serum sodium was 135mEq/L, and potassium was 4.6mEq/
L.
A preliminary diagnosis of a nonsecretory pituitary ma-
croadenoma was made, with evidence of gonadotropin deﬁ-
ciency and probable central adrenal insuﬃciency. The hyper-
prolactinemia was attributed to stalk compression rather
thanaprolactinoma,astheprolactinlevelwouldbeexpected
to be greater, typically above 200ng/mL, in a prolactin-
secreting tumor of this size. The possibility of the “hook
eﬀect” causing underestimation of the prolactin level was
excluded by obtaining a diluted prolactin level [3]. Since
the patient’s vision was at risk, she was referred for surgery.
During the course of her preoperative evaluation, a chest
radiograph was taken which showed a 7cm right hilar
mass and nodules in the apex of the left lung. Given the
patient’s extensive smoking history, the diﬀerential diagnosis
was expanded to include metastatic tumor to the sella. A
follow-up computed tomography of the chest showed a 6cm
right infrahilar mass with involvement of the subcarinal and
paraesophageal nodes as well as a 1.1cm nodule in the left
adrenal gland, highly suspicious for metastatic lung cancer
(Figure 2). In the interim, she was started on glucocorticoid
replacementforpresumptiveadrenalinsuﬃciencybecauseof
worsening nausea and the development of abdominal pain.
Her symptoms improved signiﬁcantly after glucocorticoid
replacement,anddespitelackofconﬁrmationwithanACTH
stimulation test, her clinical response was strongly suggestive
of central adrenal insuﬃciency. Two weeks later, she under-
went transsphenoidal resection of the tumor for diagnosis
and decompression of the optic chiasm. Histopathological
examinationoftheresectedpituitarylesionshowedsmallcell
carcinoma. The patient received radiation treatment to the
sellaandwasstartedonchemotherapy.Initially,shehadgood
response to single agent etoposide therapy but unfortunately
presented 18 months later with widespread brain metastases
and died shortly thereafter.
3. Discussion
This case illustrates the importance of considering pituitary
metastasis on the diﬀerential diagnosis of a sellar mass. Our
patient was initially suspected of having a benign pituitary
adenoma, by far the most common cause of a sellar lesion.
Were it not for a routine chest radiograph obtained prior
to transsphenoidal surgery, her diagnosis of lung cancer
would have been made unexpectedly on pathology. Pituitary
metastases are rare with an incidence of 0.14% to 28.1% of
all brain metastases in autopsy series and 1% to 3.6% of
patients with cancer [4, 5]. They account for less than 1%
of pituitary tumors overall [6]. Breast and lung cancer are
the most common primary sites; however, a wide range of
tumors have been reported to metastasize to the pituitary
[2]. Distinguishing between a benign pituitary adenoma and
a metastatic lesion to the pituitary is a diagnostic challenge,
both clinically and radiographically. These lesions may be
asymptomatic; in fact, often the discovery of an underlying
malignancy is made on pathology of the resected pituitary
lesion. As with any sellar lesion, “mass eﬀect” symptoms,
including headache, visual ﬁeld deﬁcits, and ophthalmo-
plegia may result from expansion of the mass within the
ﬁxed space of the sella turcica, impingement upon the optic
chiasm, or extension into the cavernous sinuses containing
cranialnerves3,4,5,and6.TheradiographicﬁndingsonCT
or MRI are not speciﬁc for pituitary metastases and cannot
reliably distinguish them from a benign adenoma [2]. Some
MRI ﬁndings that favor metastasis include thickening of the
pituitary stalk, loss of bright signal in the posterior pituitary,
isointensityonT1andT2MRIimages,invasionofcavernous
sinus, and sclerotic changes surrounding the sella turcica
[7, 8]. Benign pituitary tumors are generally indolent and
slow growing; a rapidly growing tumor with extensive or
aggressive inﬁltration into surrounding tissues should raise
suspicion for pituitary metastasis [2]. Deﬁnitive diagnosis of
pituitary metastasis requires transsphenoidal biopsy.
In the case of both primary and metastatic pituitary
tumors, hypopituitarism may ensue from compression of
the hormone-secreting cells of the anterior pituitary gland.
Making the distinction between a pituitary adenoma and
malignancy can be diﬃcult, since the systemic complications
ofmalignancy,includinganorexia,weightloss,andvomiting,
may overlap with anterior pituitary deﬁciencies, such as
adrenal insuﬃciency. One helpful feature that points to the
presence of a metastatic pituitary lesion is diabetes insipidus
(DI), since only 1% of pituitary adenomas present with DI
whereas up to 70% of metastases do so [2]. This diﬀerenceCase Reports in Medicine 3
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Figure 1:MRIbrain,(a)coronal,(b)sagital:2.0 ×1.2 ×1.1cmbilobedhomogeneousenhancingmassexpandingthesellawithcompression
of the optic chiasm.
Chest CT
Figure 2: Chest CT: 6cm right infrahilar mass with involvement of
the subcarinal and paraesophageal nodes.
has been attributed to the predilection for metastases to the
posterior pituitary lobe due to its systemic blood supply
and larger area of contact with the adjacent dura [5]. While
the literature is replete with case reports of small cell lung
cancer presenting with DI, the unusual feature of this case,
and its inherent diagnostic challenge, is our patient’s lack
of symptoms referable to DI [7, 9–13]. Although untreated
adrenal insuﬃciency can mask the hypernatremia of DI
due to the development of an SIADH picture, treatment
with glucocorticoids should expose the true source of the
defect in water balance [14, 15]. An intact thirst mechanism
and suﬃcient intake of free water may allow a patient
with DI to compensate for the lack of ADH release and
maintain normonatremia, so a normal serum sodium level,
especially in the context of untreated adrenal insuﬃciency,
does not exclude DI [5]. Our patient did not develop hy-
pernatremia, polyuria, or polydypsia upon institution of
glucocorticoid treatment, conﬁrming the absence of DI. To
further complicate matters, small-cell lung cancer may on
occasion lead to the paraneoplastic syndrome of SIADH or
even ectopic ACTH production, which could obscure defects
at the level of the pituitary and hypothalamus in metastatic
disease [16, 17].
Treatment options for metastatic pituitary lesions in-
clude surgical resection, radiation, and chemotherapy. The
decision to perform surgery should be based on the clinical
presentation, overall prognosis, and extent of the systemic
disease. In our case, since a concurrent nonsecretory pitu-
itary adenoma could not be ruled out conclusively on the
basis of a lung biopsy alone, surgical decompression was
performed with the intention of preserving vision and
relieving her headaches, and also to establish a diagnosis.
Indeed, after surgical debulking, her headaches and vision
signiﬁcantly improved. An alternative approach might have
been transsphenoidal biopsy to conﬁrm the metastasis from
SCLC, followed by local radiation and systemic chemother-
apy; however, biopsy of a sellar lesion is also high risk.
External radiation and/or chemotherapy may be used
after surgery. The prognosis is generally poor, with some
series showing a 10% 1-year survival [2]. Features related
to poor outcome include age >65 at presentation, metastasis
from small-cell lung cancer, and <1 year between the initial
diagnosis of cancer and pituitary invasion [2].4 Case Reports in Medicine
The sudden onset of headache, ophthalmoplegia, or dia-
betes insipidus in a patient with risk factors for malignancy
should raise suspicion for metastasis to the pituitary [2].
While diabetes insipidus, if present, may suggest the diag-
nosis, the absence of diabetes insipidus does not exclude
metastatic disease. A high index of suspicion is thus required
when evaluating a “pituitary tumor” in a patient with cancer
risk factors.
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